Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570984 · ClinicalTrials.gov registry record · Phase 2
Preventing Asthma in High Risk Kids
A Phase 2 study of Asthma, sponsored by Boston Children's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 13
- Study locations
NCT02570984 is a Phase 2 study of Asthma that is active but no longer recruiting, run by Boston Children's Hospital. The registered enrollment target is 200 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 13 study locations across 13 states.
The verdict
NCT02570984, a Phase 2 study of Asthma, is active but no longer recruiting, sponsored by Boston Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 13
- Study locations
Study Summary
This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omalizumab
Study Locations (13)
Arizona
- Phoenix Children's Hospital - Phoenix
California
- Rady Children's Hospital - San Diego - San Diego
Colorado
- Childrens Hospital Colorado - Aurora
Connecticut
- Connecticut Children's Hospital - Hartford
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Emory University - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Indiana
- Indiana University/Riley Children's Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570984
The ClinicalTrials.gov registry entry for NCT02570984 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02570984 reports 13 study locations spanning 13 distinct geographic areas - top geographies include Arizona, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02570984 about?
NCT02570984 is a clinical study titled "Preventing Asthma in High Risk Kids". This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction i...
What is the current status of trial NCT02570984?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2018-11-27. Estimated completion is 2028-03-31.
What conditions does trial NCT02570984 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02570984?
The interventions under investigation include: Placebo (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT02570984?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02570984 being conducted?
This trial has 13 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.